Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-01-2025 | Metastasis | Research

The poor prognosis of lacrimal gland adenocarcinoma: a clinical study and literature review

Authors: Rui Liu, Tingting Ren, Jing Li, Nan Wang, Liangyuan Xu, Qihan Guo, Hong Zhang, Jianmin Ma

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2024

Abstract

Purpose

The incidence of lacrimal gland adenocarcinoma is low. This study was designed to analyze the clinical and prognostic characteristics of lacrimal gland adenocarcinoma.

Methods

This was a clinical study and literature review; 25 patients diagnosed with lacrimal gland adenocarcinoma by histopathology were enrolled and their medical history data were collected.

Results

The incidence of bone destruction and surrounding tissue invasion was 52% and 44%, respectively. The incidence of distant metastasis of lacrimal gland adenocarcinoma was about 50%. The 5-year overall survival rate of death or metastasis was 33.5%. Age, sex, laterality, tumor size, pathology type, bone destruction, nerve or perineural invasion, invasion of peripheral tissue, T stage, AR, Her-2 and treatment had no significant correlation with lacrimal adenocarcinoma’s prognosis (P > 0.05), while the higher expression of Ki-67 may have higher risk of death or metastasis (P = 0.020).

Conclusion

The incidence of bone destruction and distant metastasis of lacrimal adenocarcinoma is high and the imaging examination is necessary to assess the risk of distant metastasis. The 5-year survival rate of death or metastasis is 33.5% and the high expression of Ki-67 predicts poor prognosis of lacrimal adenocarcinoma.

Available only for authorised users

Alkatan H, Roberts F, White VA (2018) Adenocarcinoma of the lacrimal gland. In: Grossniklaus HE, Eberhart CG, Kivelä TT (eds) WHO classification of tumours of the eye. WHO Press, Geneva

Andreasen S, Grauslund M, Heegaard S (2017) Lacrimal gland ductal carcinomas: clinical, morphological and genetic characterization and implications for targeted treatment. Acta Ophthalmol 95(3):299–306. https://doi.org/10.1111/aos.13310CrossRefPubMed

Andreoli MT, Aakalu V, Setabutr P (2015) Epidemiological trends in malignant lacrimal gland tumors. Otolaryngol Head Neck Surg 152(2):279–283. https://doi.org/10.1177/0194599814556624CrossRefPubMed

Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV (2020) Androgen receptor in breast cancer-clinical and preclinical research insights. Molecules 25(2):358. https://doi.org/10.3390/molecules25020358CrossRefPubMedPubMedCentral

Ashok Kumar P, Paulraj S, Mirchia K et al (2020) Ductal adenocarcinoma ex pleomorphic adenoma of the lacrimal gland: a rare and morbid malignancy. Case Rep Oncol Med 2020:1790106. https://doi.org/10.1155/2020/1790106CrossRefPubMedPubMedCentral

Ashok Kumar P, Wang D, Huang D, Paulraj S, Sivapiragasam A (2022) Current trends in the management of epithelial lacrimal gland tumors: a retrospective national cancer database analysis. Cureus 14(7):e27109. https://doi.org/10.7759/cureus.27109CrossRefPubMedPubMedCentral

Aucoin AJ, Chawla H, Holleman GT et al (2023) Primary ductal adenocarcinoma of the lacrimal gland with sarcomatoid differentiation: case report and genomic analysis. Orbit. https://doi.org/10.1080/01676830.2023.2246156CrossRefPubMed

Bulbul A (2018) Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation. Oxf Med Case Rep 2018(9):omy066. https://doi.org/10.1093/omcr/omy066CrossRef

Damasceno RW, Holbach LM (2012) Primary ductal adenocarcinoma of the lacrimal gland: case report. Arq Bras Oftalmol 75(1):64–66. https://doi.org/10.1590/s0004-27492012000100014CrossRefPubMed

Dennie T (2015) Metastatic, her-2 amplified lacrimal gland carcinoma with response to lapatinib treatment. Case Rep Oncol Med 2015:262357. https://doi.org/10.1155/2015/262357CrossRefPubMedPubMedCentral

Fakhril-Din Z, Kiss K, Lund EL et al (2023) Adenocarcinoma in situ (ductal type) ex pleomorphic adenoma of the lacrimal gland. Am J Ophthalmol Case Rep 31:101855. https://doi.org/10.1016/j.ajoc.2023.101855CrossRefPubMedPubMedCentral

Garakani R, Kersten R, Pekmezci M (2020) Intracapsular high-grade ductal carcinoma in-situ ex pleomorphic adenoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg 36(1):e1–e3. https://doi.org/10.1097/IOP.0000000000001491CrossRefPubMed

Goto H, Yamakawa N, Komatsu H, Asakage M, Tsubota K, Ueda SI, Nemoto R, Umazume K, Usui Y, Mori H (2021) Clinico-epidemiological analysis of 1000 cases of orbital tumors. Jpn J Ophthalmol 65(5):704–723. https://doi.org/10.1007/s10384-021-00857-1CrossRefPubMed

Gündüz K, Shields CL, Günalp I et al (2003) Magnetic resonance imaging of unilateral lacrimal gland lesions. Graefes Arch Clin Exp Ophthalmol 241(11):907–913. https://doi.org/10.1007/s00417-003-0748-zCrossRefPubMed

Issiaka M, Ayyadi S, El Belhadji M (2021) De novo adenocarcinoma of the lacrimal gland: case report. Ann Med Surg (lond) 64:102234. https://doi.org/10.1016/j.amsu.2021.102234CrossRefPubMed

Katz SE, Rootman J, Dolman PJ et al (1996) Primary ductal adenocarcinoma of the lacrimal gland. Ophthalmology 103(1):157–162. https://doi.org/10.1016/s0161-6420(96)30746-xCrossRefPubMed

Kim MJ, Hanmantgad S, Holodny AI (2008) Novel management and unique metastatic pattern of primary ductal adenocarcinoma of the lacrimal gland. Clin Exp Ophthalmol 36(2):194–196. https://doi.org/10.1111/j.1442-9071.2008.01704.xCrossRefPubMed

Kim JS, Proia AD, Liss J et al (2022) Multiple cranial neuropathies as the initial presentation of primary ductal adenocarcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg 38(3):e75–e77. https://doi.org/10.1097/IOP.0000000000002111CrossRefPubMed

Krishnakumar S, Subramanian N, Mahesh L et al (2003) Primary ductal adenocarcinoma of the lacrimal gland in a patient with neurofibromatosis. Eye (lond) 17(7):843–845. https://doi.org/10.1038/sj.eye.6700476CrossRefPubMed

Kubota T, Moritani S, Ichihara S (2013) Clinicopathologic and immunohistochemical features of primary ductal adenocarcinoma of lacrimal gland: five new cases and review of literature. Graefes Arch Clin Exp Ophthalmol 251(8):2071–2076. https://doi.org/10.1007/s00417-013-2350-3CrossRefPubMed

Kurisu Y, Shibayama Y, Tsuji M et al (2005) A case of primary ductal adenocarcinoma of the lacrimal gland: histopathological and immunohistochemical study. Pathol Res Pract 201(1):49–53. https://doi.org/10.1016/j.prp.2004.11.003CrossRefPubMed

Lau LL, Lung CK, Ahmad SS (2015) A benign presentation of primary ductal adenocarcinoma of lacrimal gland: a rare malignancy. Indian J Ophthalmol 63(11):856–858. https://doi.org/10.4103/0301-4738.171969CrossRefPubMedPubMedCentral

Lee YJ, Oh YH (2009) Primary ductal adenocarcinoma of the lacrimal gland. Jpn J Ophthalmol 53(3):268–270. https://doi.org/10.1007/s10384-008-0659-yCrossRefPubMed

Lee CM, Chung IY, Park Y, Yun KW, Jo HG, Park HJ, Lee HJ, Lee SB, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Kim J (2020) The impact of androgen receptor and histone deacetylase 1 expression on the prognosis of ductal carcinoma in situ. J Breast Cancer 23(6):610–621. https://doi.org/10.4048/jbc.2020.23.e68CrossRefPubMedPubMedCentral

Luna-Ortiz K, Dominguez-Malagon H, Corredor-Alonso GE, Reynoso-Noveron N, Herrera-Ponzanelli C, Luna-Peteuil Z, Zacarias-Ramon LC (2022) Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. Eur Arch Otorhinolaryngol 279(1):327–333. https://doi.org/10.1007/s00405-021-06757-xCrossRefPubMed

Milman T, Shields JA, Husson M et al (2005) Primary ductal adenocarcinoma of the lacrimal gland. Ophthalmology 112(11):2048–2051. https://doi.org/10.1016/j.ophtha.2005.04.029CrossRefPubMed

Min KW, Park HK, Kim WY et al (2014) Primary ductal adenocarcinoma of the lacrimal gland, associated with abundant intracytoplasmic lumens containing some eosinophilic hyaline globules: cytological, histological and ultrastructural findings. Ultrastruct Pathol 38(5):363–366. https://doi.org/10.3109/01913123.2014.921656CrossRefPubMed

Patel SR, Cohen P, Barmettler A (2018) Primary ductal adenocarcinoma of the lacrimal gland with changing genetic analysis mutations. Orbit 37(6):463–467. https://doi.org/10.1080/01676830.2018.1437191CrossRefPubMed

Ravaioli S, Maltoni R, Pasculli B, Parrella P, Giudetti AM, Vergara D, Tumedei MM, Pirini F, Bravaccini S (2022) Androgen receptor in breast cancer: the “5W” questions. Front Endocrinol (lausanne) 13:977331. https://doi.org/10.3389/fendo.2022.977331CrossRefPubMed

Ricci M, Amadori E, Chiesa F et al (2014) Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. Future Oncol 10(10):1735–1739. https://doi.org/10.2217/fon.14.36CrossRefPubMed

See TRO, Stålhammar G, Tang T, Manusow JS, Jordan DR, Nerad JA, Kersten RC, Yonkers M, Syed NA, Brownstein S, Grossniklaus HE (2020) Primary ductal adenocarcinoma of the lacrimal gland: a review and report of five cases. Surv Ophthalmol 65(3):371–380. https://doi.org/10.1016/j.survophthal.2019.11.002CrossRefPubMed

Touil A, El Abbassi S, Echchikhi Y, Maher M, Kebdani T, Benjaafar N (2017) Adenocarcinoma of the lacrimal gland: a case report. J Med Case Rep 11(1):257. https://doi.org/10.1186/s13256-017-1412-2CrossRefPubMedPubMedCentral

Udager AM, Chiosea SI (2017) Salivary duct carcinoma: an update on morphologic mimics and diagnostic use of androgen receptor immunohistochemistry. Head Neck Pathol 11(3):288–294. https://doi.org/10.1007/s12105-017-0798-xCrossRefPubMedPubMedCentral

Yang HY, Wu CH, Tsai CC, Yu WK, Kao SC, Liu CJ (2018) Primary ductal adenocarcinoma of lacrimal gland: two case reports and review of the literature. Taiwan J Ophthalmol 8(1):42–48. https://doi.org/10.4103/tjo.tjo_3_18CrossRefPubMedPubMedCentral

Yang S, Chen W, Chen W et al (2023) Androgen receptor increases and negative expression of GCDFP-15 in primary ductal adenocarcinoma of the lacrimal gland: a case description. Quant Imaging Med Surg 13(2):1200–1205. https://doi.org/10.21037/qims-22-312CrossRefPubMedPubMedCentral

Zhu MM, Cui HG, Teng XD (2015) GCDFP-15, AR, and Her-2 as biomarkers for primary ductal adenocarcinoma of the lacrimal gland: a Chinese case and literature review. Onco Targets Ther 8:1017–1024. https://doi.org/10.2147/OTT.S82168CrossRefPubMedPubMedCentral

Title: The poor prognosis of lacrimal gland adenocarcinoma: a clinical study and literature review
Authors: Rui Liu
Tingting Ren
Jing Li
Nan Wang
Liangyuan Xu
Qihan Guo
Hong Zhang
Jianmin Ma
Publication date: 01-01-2025
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Radiotherapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05510-7

Gastroenteropancreatic neuroendocrine carcinoma in children and adolescents: a population-based study

Cytostatic Therapy
Original Research

Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials

Open Access
Trastuzumab
Original Research

Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis

Open Access
NSCLC
Review

Mitophagy plays a “double-edged sword” role in the radiosensitivity of cancer cells

Open Access
Ionizing Radiation
Review

Effect of radiation therapy on patients with stage T3 or T4 malignant phyllodes tumors: a retrospective observational study based on SEER

Open Access
Mastectomy
Original Research

Incidence of second malignancies in patients with thymic carcinoma and thymic neuroendocrine tumor

Open Access
Neuroendocrine Tumor
Original Research

Keynote series | Spotlight on managing health in obesity

Obesity
Video Series

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman

Prof. Jonette Keri

Developed by: Springer Medicine

Watch now

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

The poor prognosis of lacrimal gland adenocarcinoma: a clinical study and literature review